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Objective: Acquired laryngotracheal stenosis is a potentially life-threatening situation and a very difﬁcult and challenging
problem in laryngology. Therefore, new trends and innovative approaches based on antiﬁbrotic drugs and minimally invasive
regimens are being developed to attenuate laryngotracheal ﬁbrosis and scarring. The purpose of this study was to examine the
efﬁcacy of mitomycin-C (MMC) to reverse the transforming growth factor (TGF)-β-induced differentiation of MRC-5 ﬁbroblast
and human primary vocal cord ﬁbroblasts to reveal the possible applicability of MMC to laryngotracheal ﬁbrotic conditions.
Methods: Human primary ﬁbroblast cells were isolated from vocal cord specimens of patients undergoing total laryngec-
tomy. The established primary vocal cord ﬁbroblast cell cultures as well as the MRC-5 human ﬁbroblast cells were treated with
5 ng/mL TGF-β alone and then with 0.5 μg/mL MMC for 24 hours. Differentiation of ﬁbroblasts was characterized by α-smooth
muscle actin (α-SMA) immunhistochemistry, Western blot analysis, and real-time polymerase chain reaction. Cell motility was
assessed by wound-healing assay.
Results: Elevated α-SMA mRNA and protein expression as well as increased cell motility were observed upon TGF-β expo-
sures. However, after MMC treatments the TGF-β-induced ﬁbroblasts exhibited a signiﬁcant decrease in α-SMA expression and
wound-healing activity. Therefore, TGF-β-stimulated ﬁbroblast-myoﬁbroblast transformation was reversed at least in part by
MMC treatment. Histopathological examinations of tissue specimens of a laryngotracheal stenosis patient supported these
ﬁndings.
Conclusion: Antiﬁbrotic effects of MMC were demonstrated on the human MRC-5 cell line and on primary vocal cord
ﬁbroblast cultures. These results verify that MMC can be used with success to reverse upper airway stenosis by reverting the
myoﬁbroblast phenotype.
Key Words: Laryngotracheal stenosis, antiﬁbrotic effects, mitomycin-C, primary vocal cord ﬁbroblast, α-smooth
muscle actin.
Level of Evidence: NA
Laryngoscope, 00:1–8, 2019
INTRODUCTION
In response to injury, inﬂammation, exposure to
toxic substances, or physical trauma, tissues initiate heal-
ing processes; however, ﬁbrotic diseases may develop if
these reparative mechanisms are misregulated.1,2 Patho-
physiological progression of ﬁbrotic conditions eventually
lead to organ failure; thus, ﬁbrosis can be accounted for
millions of deaths worldwide. Generally, ﬁbrotic diseases
are characterized by excessive differentiation of ﬁbro-
blasts to myoﬁbroblasts, resulting in a cell type capable of
contraction due to elevated alpha-smooth muscle actin
(α-SMA) expression, as well as of accumulating extracel-
lular matrix components following increased synthesis in
the affected tissues. Although ﬁbrosis can occur in various
organs, and the underlying etiologies might be substan-
tially different, mechanistically the pleiotropic transform-
ing growth factor β (TGF-β) is the most frequent trigger
for ﬁbroblast differentiation in such conditions.
Based on own observations, although the highest
incidence of ﬁbrotic disease affects lungs, kidneys, and
the liver, the frequency of ﬁbrosis-related disorders in
other organs such as the vocal cords and trachea has been
progressively and alarmingly increased in recent years.
Such an example is iatrogenic laryngotracheal stenosis
(LTS), which is a serious end result of uncontrolled tra-
cheal ﬁbrotic processes.3 Previous investigations in our
clinic revealed that the pathogenesis of LTS is multifacto-
rial4; however, the most common cause is mechanical
trauma derived from endotracheal intubation. Depending
on the exact anatomical region, a sustained compression
of the tracheal tube’s cuff on the tracheal wall may cause
blood circulation failure, inﬂammation, scarring in soft
tissue, and even cartilage damage. Although minimally
invasive treatment modalities have been implemented to
manage LTS in most cases,5–7 surgical resection, tracheal
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reconstructions, and end-to-end anastomosis must be
applied as a deﬁnitive treatment even if these have mod-
erate efﬁciency due to high risk of granulation tissue for-
mation and restenosis.8,9 Considering several factors such
as high risk of surgery, postoperative complications,
extended hospitalization period after surgery, and sub-
stantial costs, new trends and innovative approaches of
LTS treatment are mandatory.
For modulation of wound-healing processes and for
attenuating scarring, one of the possible solutions described
in the scientiﬁc literature is the application of antiﬁbrotic
drugs on primary lesions. For this purpose, various antiﬁ-
brotic pharmaceutical agents such as corticosteroids,10
5-ﬂuorouracil,11 carnitine, and mitomycin-C (MMC)12,13
have already been employed either alone in short-term local
surface applications or as at our clinic in combination with
preceding laser excision of cicatricle tissue in laryngotra-
cheal stenosis treatment. Although MMC is a traditional
chemotherapeutic drug, isolated from Streptomyces sp., it
has also been regarded as a compound with high potential
to prevent tissue ﬁbrosis. The antiﬁbrotic activity of locally
applied MMC is presumably due to its inhibiting effects on
ﬁbroblast proliferation14–16; however, clinical and experi-
mental data considering its application in ﬁbrosis and LTS
treatment are still elusive.17,18 Although some clinical
observations suggest the possible applicability of MMC for
laryngotracheal ﬁbrotic conditions, its efﬁcacy on LTS
requires more mechanistic and detailed investigations.
Thus, using the human MRC-5 ﬁbroblasts cell line and
patient-derived primary laryngotracheal ﬁbroblasts, we
established TGF-β-induced ﬁbrosis models to investigate
the antiﬁbrotic potential of MMC.19–21
MATERIALS AND METHODS
Culturing MRC-5 Fibroblasts
The MRC-5 human ﬁbroblast cell line (Sigma-Aldrich,
St. Louis, MO) was cultured in Eagle’s Minimum Essential
Medium (EMEM) complemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 0.001% streptomycin, and 0.005%
penicillin under standard conditions.
Isolation and Culturing of Human Primary
Fibroblasts
Human primary ﬁbroblast cells were isolated from vocal
cord specimens of human patients undergoing total laryngectomy
due to laryngeal cancer. The larynx was removed, and the
healthy part of the vocal cord was resected and placed in
phosphate-buffered saline immediately. The tissue sample con-
tained epithelium, lamina propria, and muscle tissue. The
resected vocal cord was cut into 1 × 1 mm pieces, which were
then placed into precoated T25 ﬂasks in culture medium (EMEM
supplemented with 10% FBS, 100 U/mL penicillin, 0.01 mg/mL
streptomycin, 2 mM L-glutamine) and were kept at 37C in 5%
CO2 atmosphere and 95% humidity. When ﬁbroblast cultures
started to grow, the medium was frequently changed. When 80%
of the surface was covered with ﬁbroblasts, the tissue pieces were
removed, the cells were allowed to reach conﬂuence, and then
cells were trypsinized and passaged to new ﬂasks. Cultured ﬁbro-
blast was used between 4 to 8 passages.
Immunocytochemistry
To verify that the obtained patient-derived cells were ﬁbro-
blasts, cells were stained for α-SMA and vimentin. For this, cells
were grown on coverslips and ﬁxed by 4% formaldehyde (PFA)
solution. Following permeabilization with 0.3% Triton-X-100
(Sigma) solution, the samples were blocked in 5% bovine serum
albumin (BSA) (Sigma) and stained with α-SMA- and vimentin-
speciﬁc primary antibodies (Abcam) overnight. On the following
day, ﬂuorophore-conjugated secondary antibodies (Abcam) were
applied and cell nuclei were counterstained with DAPI (Sigma).
Samples were visualized by an Olympus BX51 ﬂuorescent micro-
scope equipped with Olympus DP70 camera (Tokyo, Japan).
Fibroblast Differentiation and Mitomycin-C
Treatment
MRC-5 and primary vocal cord ﬁbroblast cells were treated
with 5 ng/mL TGF-β (Abcam) diluted in 2% serum-containing
culture medium for 48 hours. After 24 hours, MMC was added to
the TGF-β-containing medium in 0.5 μg/mL concentration (deter-
mined by viability measurements), and cells were incubated for
an additional 24 hours (Barcelona, Spain).
Measurement of Cytotoxicity, Proliferation, and
Apoptosis
Impedance-based dynamic monitoring of living adherent
cells was carried out with xCELLigence RTCA System (Roche
Applied Science, Mannheim, Germany). 5,000 cells/well were
loaded onto special 96-well E-plates with built-in gold electrodes
and were covered with culture medium. After cells reached
steady growth, they were treated with various concentrations
(0.1, 0.3, 0.5, 1, 3, 5 μg/mL) of MMC. To assess the toxicity of
MMC (Inibsa) real-time, the impedance of the cells was regis-
tered every 10 minutes, and for each time point a cell index was
calculated based on the measured values in the presence and in
absence of cells. Based on these measurements, a nontoxic con-
centration for MMC could be determined, which was used
throughout further cell treatments.
To detect cell proliferation, MRC-5 cells were seeded to
24-well plates and treated with 5 ng/mL TGF-β and/or MMC
diluted in 2% serum containing medium. Cells were collected each
day by trypsinization, and the number of cells/well was determined
using a Vi-CELL XR cell counter (Beckman Coulter, Brea, CA).
For cytotoxicity measurements, MRC-5 cells were seeded into
96-well plates in 5,000 cells/well density. On the following day,
cells were treated with 5 ng/mL TGF-β diluted in 2% serum con-
taining medium for 48 hours. After 48 hours, MMC was added to
the TGF-β-containing medium, and cells were treated for further
48 hours. At the end of the treatment, cell viability was deter-
mined using CellTiter Aqueous One cell proliferation assay
(Promega, Madison, WI), and absorbance was determined in a Syn-
ergy HTX multimode reader. Upon calculating cell viability, values
corresponding to nonstimulated cells were considered 100%. For
apoptosis detection, MRC-5 cells were seeded into black-wall
96-well plates (Thermo), and the same experimental protocol was
used as described above. As a readout, Apo-ONE homogeneous
Caspase-3/7 Assay (Promega) was applied using a FLUOstar
Omega plate reader (BMG Labtech, Offenburg, Germany).
Western Blot
To analyse α-SMA protein levels, Western blot analysis was
performed. MRC-5 and primary vocal cord ﬁbroblast cells were
grown in T25 culture ﬂasks. Following treatments with either
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TGF-β or MMC or both, cells were scraped, collected by centrifuga-
tion, and lysed in Radioimmunoprecipitation assay buffer (RIPA)
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1%
Sodium dodecyl sulfate (SDS), 1% Triton-X-100). Protein concen-
trations were determined using the BCA method, and then 25 μg
total protein from each sample was resolved on 8% SDS-
polyacrylamide gel. After electrophoresis, proteins were trans-
ferred to nitrocellulose membranes (Amersham). The membranes
were blocked with 5% nonfat dry milk-TBST solution, and then
α-SMA-speciﬁc primary antibody (Abcam) was applied overnight
in 1:2000 dilution and Tubulin-speciﬁc antibody (Sigma, 1:2000)
was hybridized to the membranes to ensure equal loading.
HRP-conjugated secondary antibodies (Dako) were used, and then
membranes were developed using Immobilon Western HRP sub-
strate (Millipore). Chemiluminescent signal was detected in a Li-
Cor C-Digit blot scanner (Li-Cor Biotech., Cambridge, U.K.).
Scratch Assay
To measure the migration activity of MRC-5 and primary
vocal cord ﬁbroblasts, cells were left to grow in 6-well plates until
they reached conﬂuence. Next, cell layers were then treated with
5 ng/mL TGF-β for 24 hours, and then wounds were created
using a P200 pipette tip. Cell-free zones were photographed with
a phase-contrast microscope, and then 0.5 μg/mL MMC was
added to the cells. After 24-hour treatment, samples were photo-
graphed again, and the number of migrating cells were counted
using ImageJ1.44 software.
qPCR
For real-time quantitative polymerase chain reaction
(RT-qPCR) analysis, 6 × 105 cells were seeded into 6-cm diameter
culture dishes. On the following day, cells were treated with TGF-β,
and then 24 hours later MMC was added to the culture for an addi-
tional 24 hours of treatment. Total RNA was isolated using RNeasy
Mini Kit (Qiagen, Hilden, Germany) according to the guidelines of
the manufacturer. Taqman Reverse Transcription Reagent
(Applied Biosystems, Foster City, CA) was applied to generate
cDNA using 1 μg of total RNA, and relative levels of TGF-β,
COL1A1, PAI-1, and CTGF transcripts were quantiﬁed in a Pico
Real-Time qPCR System (Thermo Scientiﬁc) using gene-speciﬁc
primers (Table I) and SYBR Green PCR Master Mix (Applied Bio-
systems). The level of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH)-speciﬁc messengers was measured to calculate relative
amount of each transcript using ΔΔCt analysis. RT-qPCR measure-
ments were carried out in triplicates.
Immunohistochemistry of Patient Samples
Samples were obtained from a patient undergoing laser
excision of the posterior glottis stenosis and receiving topical
MMC treatment 1 week following scar excision. Tissue samples
were ﬁxed in 10% formaldehyde and 4-μm thick parafﬁn sections
were prepared. The specimens were incubated with α-SMA-
speciﬁc primary antibody (Cellmarque Corp., Rocklin, CA) in
1:300 dilution at pH 9. Throughout the staining, the EnVision
FLEX kit on Dako Autostainer Plus (Dako) protocol was used.
α-SMA-positive cells were counted by ImageJ1.44 software with
a CellCounter plugin on four independent ImageJ/sample.
Statistical Analysis
Statistical analysis and graphical visualization of the
obtained data were carried out in a GraphPad Prism 7.0 software
(GraphPad Software Inc., La Jolla, CA) using t test and two-way
analysis of variance (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤
0.0001 and # P = 0.0006 indicate statistical signiﬁcance).
RESULTS
MMC Hampers TGF-β-Triggered MRC-5
Fibroblast Transformation
To test the antiﬁbrotic potential of MMC, we ﬁrst
evaluated its cytotoxicity on MRC-5 human ﬁbroblast
cells. These cells represent a generally accepted and
widely utilized in vitro model system for studying cellular
and molecular mechanisms in the background of ﬁbrotic
diseases. MRC-5 cells received increasing concentrations
of MMC, and the dose response of the treatments was
obtained by real-time cell electronic sensing. Upon MMC
exposure, ﬁbroblast cells showed gradually decreasing
cell indices suggesting a dose-dependent antiproliferative
effect of MMC (Fig. 1A). Differences in the kinetic curves
indicated that 5 μg/mL MMC exhibited serious toxicity
throughout the examined time period; however, MMC
concentrations between the 0.1 and 1 μg/mL range proved
to be sublethal.
To test that MMC also exhibits similar effects on TGF-
β-transformed ﬁbrotic cells, MRC-5 cells were treated with
either TGF-β or with MMC (in 0.5 or 5 μg/mL concentra-
tions) or with TGF-β+MMC combinations, and cell prolifera-
tion was monitored for 5 days (Fig. 1B). TGF-β-stimulated
ﬁbroblasts showed elevated proliferative activity compared
to nonstimulated cells because the TGF-β-exposed cells
reached the plateau phase already after 72 hours, whereas
control ﬁbroblasts accomplished this cell number only after
120 hours. Similar to what we observed earlier, 0.5 μg/mL
MMC exhibited cytostatic effect, whereas treatments with
5 μg/mL MMC proved to be cytotoxic on nonstimulated
TABLE I.
Primer Sequences.
Target Forward Primer Reverse Primer
GAPDH 50-GCACCGTCAAGGCTGAGAAC-30 50-TGGTGAAGACGCCAGTGGA-30
TGF-β 50-AGCAACAATTCCTGGCGATAC-30 50-CTAAGGCGAAAGCCCTCAAT-30
COL1A1 50-CATCTGGTGGTGAGACTTGC-30 50-TCCTGGTTTCTCCTTTGG-30
PAI-1 50-AGTGGACTTTTCAGAGGTGGAG-30 50-GCCGTTGAAGTAGAGGGCATT-30
CTGF 50-GGAAATGCTGCGAGGAGTGG-30 50-GGCTCTAATCATAGTTGGGTCTGG-30
CTGF = connective tissue growth factor; COL1A1 = collagen alpha-1(1); GAPDH = glyceraldehyde 3-phosphate dehydrogenase; PAI-1 = plasminogen
activator inhibitor-1; TGF = transforming growth factor.
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MRC-5 cells. Most importantly, MMC treatments exerted
comparable effects on TGF-β-transformed cells as on nonsti-
mulated cells, proving the antiproliferative activity of MMC
on transformed ﬁbroblasts as well. To compare the apopto-
tic and cytotoxic activity of MMC on ﬁbrotic cells, nonstimu-
lated and TGF-β-transformed cells were treated with MMC
in various concentrations for 48 hours, and then Caspase
3/7 activity measurement (Fig. 1C) or cell viability assay
(Fig. 1D) was performed. MMC treatments decreased cell
viability in a dose-dependent manner both in naïve and
TGF-β-transformed ﬁbroblasts. Five and 10 μg/mL MMC
induced signiﬁcant induction in Caspase 3/7 activity. More-
over, treatments with 10 μg/mL MMC triggered Caspase
3/7 activity with a signiﬁcantly higher degree in trans-
formed ﬁbroblasts than in the nonstimulated counterparts.
Because elevated cell migration during cicatrix for-
mation is one of the characteristic hallmarks of ﬁbrotic
cells, we tested the migration capacity of scratch-
activated MRC-5 ﬁbroblasts upon MMC treatment. For
this, MRC-5 cells were cultured until they reached conﬂu-
ence, and then wounds were scratched into the cell layers
using sterile pipette tips. After scratching, cells were
Fig. 1. (A–G) Dose response of MMC treatment (A) and effect of MMC on TGF-β-triggered MRC-5 ﬁbroblast transformation, assessed by prolif-
eration (B), Caspase 3/7 activity (C), viability (D), wound-healing assay (E), Western blot (F), and quantitative polymerase chain reaction (G).
MMC = mitomycin-C; SMA = smooth muscle actin; TGF = transforming growth factor.
Laryngoscope 00: 2019 Szabó et al.: Laryngeal Stenosis Treatment With Mitomycin-C
4
incubated for 24 hours either in the presence or in the
absence of 0.5 ug/mL MMC. Cell-free zones were photo-
graphed, and then the number of cells that had migrated
into the cell-free zones was determined using software-
based ImageJ1 analysis. We found that MMC treatment
signiﬁcantly decreased the scratch-triggered migration of
MRC-5 ﬁbroblast cells (Fig. 1E).
Because elevated TGF-β secretion is responsible for
maintaining ﬁbroblasts in the activated phenotype during
the development of ﬁbrotic diseases,22 we tested whether
MMC treatment can inﬂuence the TGF-β-provoked
ﬁbroblast-to-myoﬁbroblast transformation. For this, serum-
starved MRC-5 cells were treated with TGF-β in 0.5 ng/mL
concentration for 24 hours, and then MMC was added to
the culture and the cells were incubated for an additional
24 hours. To detect ﬁbroblast transformation, α-SMA
protein expression—a well-recognized marker of ﬁbrotic
ﬁbroblasts—was monitored by Western blotting. As
expected, TGF-β alone induced substantial ﬁbroblast trans-
formation because we observed highly elevated α-SMA
expression in these cells compared to untreated ﬁbroblasts.
Although MMC alone did not inﬂuence α-SMA expression
in nonstimulated ﬁbroblasts, we found that MMC treat-
ment effectively attenuated the ﬁbroblast-transforming
effect of TGF-β treatments (Fig. 1F). To verify this
antiﬁbrotic activity of MMC, total RNA was isolated from
TGF-β-stimulated and MMC-treated MRC-5 ﬁbroblasts,
and mRNA levels of ﬁbrotic marker genes TGF-β, COL1A1,
PAI-1, and CTGF were quantiﬁed by qPCR measurements.
TGF-β alone induced signiﬁcant upregulation in the expres-
sion of every examined ﬁbrosis marker gene, although this
effect was signiﬁcantly abolished when TGF-β-exposed
ﬁbroblasts were treated with MMC as well (Fig. 1G). It is
also noteworthy that MMC treatment alone resulted in
lower expression levels of COL1A1 and CTGF in MMC-
exposed cells compared to those of control MRC-5
ﬁbroblasts.
MMC Exhibits Antiﬁbrotic Effects in Patient-
Derived Primary Vocal Cord Fibroblasts
Because we found that MMC displays a remarkable
antiﬁbrotic activity in MRC-5 ﬁbroblast cells, we decided
to test its efﬁciency on patient-derived primary vocal cord
ﬁbroblast cells as well. Three patients attending our clinic
underwent total laryngectomy due to laryngeal cancer.
Healthy parts of vocal cords were used to initiate primary
human ﬁbroblast cultures. Primary cells showed ﬁbro-
blast characteristics such as spindle-like morphology;
moreover, they stained positive for the ﬁbroblast markers
Fig. 2. (A–C) Veriﬁcation of patient-derived ﬁbroblast cells by immunocytochemistry (A). Effect of MMC on TGF-β-triggered patient-derived pri-
mary vocal cord ﬁbroblasts transformation by Western blot (B) and wound-healing assay (C). MMC = mitomycin-C; SMA = smooth muscle
actin; TGF = transforming growth factor.
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α-SMA and vimentin and thus were proven to be primary
ﬁbroblast cultures (Fig. 2A).
To test the efﬁcacy of MMC on the obtained primary
ﬁbroblasts, ﬁrst, wound healing assays were performed.
Primary ﬁbroblasts were left to grow, and wounds were
scratched when cells reached conﬂuence. Similar to MRC-
5 ﬁbroblasts, patient-derived cells were also treated with
MMC in 0.5 μg/mL concentration for 24 hours, and then
the number of cells that migrated to cell-free zones were
counted. We found that MMC treatment signiﬁcantly
inhibited scratch-induced migration of all three of the
examined patient-derived primary ﬁbroblasts (Fig. 2B).
To examine whether MMC can inﬂuence the ﬁbrosis-
mediating potential of TGF-β in primary ﬁbroblasts, like-
wise to the MRC-5 ﬁbroblast cell line, serum-starved
primary cells were treated with 5 ng/mL TGF-β. Twenty-
four hours later, MMC was added to the medium in 0.5
ug/mL concentration, and cells were incubated for further
24 hours. We detected the expression of the ﬁbrotic ﬁbro-
blast and myoﬁbroblast marker α-SMA by Western blot-
ting, which indicated that TGF-β triggered considerable
ﬁbroblast activation in all three of the treated primary
ﬁbroblast lines. Western blot data show that MMC treat-
ment in primary ﬁbroblasts hindered the ﬁbrosis-
inducing effect of TGF-β treatment in all three of the
examined cases. Moreover, in cells obtained from patient
03, MMC treatments were able to completely restore the
basal phenotype of TGF-β-stimulated ﬁbroblasts because
α-SMA level of the TGF-β+MMC-treated cells was compa-
rable to that of the nontreated control cells (Fig. 2C).
Topical MMC Treatment Reduces Laryngeal
Fibrosis In Vivo
Histopathological veriﬁcation of highly effective
MMC treatment on a patient diagnosed with posterior
commissure stenosis is shown in Figure 3 as a represen-
tative case. Prior to MMC treatment, tissue samples were
obtained from the ﬁbrotic area and also from the healthy
adjacent tissue. Then, the patient received topical MMC
treatment two times: after 1 week and 2 weeks after laser
resection of posterior commissure stenosis. Two weeks
after the second topical MMC treatment, specimens were
resected from MMC-treated tissue and subjected to post-
treatment histopathology. As expected, the healthy tissue
region stained negative to the ﬁbrosis marker α-SMA,
whereas a strong positive staining was detected in the
ﬁbrotic area. Strikingly, after MMC treatment markedly
lower expression of the ﬁbrosis marker α-SMA was
observed following immunohistochemical staining and
subsequent pathological examination, and the staining
intensity was comparable to that of the healthy tissue
sample (Fig. 3.). Quantiﬁcation of α-SMA-positive cells in
tissue sections veriﬁed the high expression of α-SMA in
ﬁbrotic tissues, which was suppressed by MMC
treatment.
DISCUSSION
Acquired laryngotracheal stenosis is a potentially
life-threatening condition, induced mainly by traumatic
and prolonged endotracheal intubation.23 In most cases,
LTS complications signiﬁcantly inﬂuence the patient’s life
qualities because symptoms may vary from mild dyspnea
and stridor to serious respiratory failure.24 In the last
decades, due to a signiﬁcant increase in intensive care
interventions worldwide, the frequency of iatrogenic LTS
events has been substantially elevated and thus a
demand for novel treatment modalities.25
In our study, we proved that MMC is effective in
attenuating TGF-β-induced ﬁbroblast-to-myoﬁbroblast
transformation not only on the well-established human
Fig. 3. Topical MMC treatment reduces laryngeal ﬁbrosis in vivo veriﬁed by α-SMA immunohistochemistry. H&E = hematoxylin and eosin; MMC =
mitomycin-C; SMA = smooth muscle actin.
Laryngoscope 00: 2019 Szabó et al.: Laryngeal Stenosis Treatment With Mitomycin-C
6
MRC-5 ﬁbroblast model system but also on patient-
derived primary vocal cord ﬁbroblasts. To verify this anti-
ﬁbrotic activity and the inhibitory action of MMC on
ﬁbroblast differentiation, the proliferation, wound-healing
activity, apoptotic potential, α-SMA expression, and the
mRNA levels of ﬁbrotic marker genes (TGF-β, COL1A1,
PAI-1, and CTGF) were quantiﬁed in TGF-β-stimulated
and MMC-treated ﬁbroblasts, respectively. Importantly,
we demonstrated the beneﬁcial effect of topical MMC
treatment using histological staining results of a patient
with posterior commissure stenosis, for which we
observed a markedly lower expression level of the ﬁbrosis
marker α-SMA after MMC treatment and thereby con-
ﬁrmed the in vivo competence of MMC.
The antiﬁbrotic potential of MMC has been tested in
various human and animal in vivo, as well as in numer-
ous in vitro model systems. MMC was shown to reduce
pericardial ﬁbrosis after cardiac surgery in rabbits26 and
to decrease the postoperative ﬁbrosis after glaucoma sur-
gery.27 Its antiﬁbrotic effect was conﬁrmed in human
Tenon’s capsule ﬁbroblast cultures in vitro,28 in a rat
Peyronie’s disease model,29 and in an experimentally
induced urethral stricture model in rats.30 Furthermore,
MMC could prevent bronchial stenosis in a young cystic
ﬁbrosis patient following bilateral lung transplantation.31
We believe that the antiﬁbrotic effect of MMC also
can be exploited by LTS patients. According to our
hypothesis, the maximal in vivo antiﬁbrotic activity can
be achieved if the treatment with MMC occurs in the
granulation phase of the wound-healing process, which is
when ﬁbroblast proliferation is activated.32–37 In fact,
rudimentary tissue generation relies mainly on ﬁbro-
blasts that migrate into the wound area and ultimately
transform into myoﬁbroblasts, which is induced by the
action of TGF-β.38–41 The presence of myoﬁbroblasts in
the regenerating tissue is a positive marker of progres-
sive ﬁbrosis, although their number usually decreases as
the wound is closed. Experimental and clinical observa-
tions imply that topical MMC application should be
started not earlier than 1 week after laser excision of ste-
notic tissue to inhibit myoﬁbroblast overproduction and
thereby prevent restenosis. Moreover, we expect that
MMC treatment can reduce ﬁbrosis with the highest efﬁ-
ciency by patients with LTS in a long-term application
regime, in contrast to the moderate ﬁbrosis inhibiting
effect of early, short-term MMC application observed by
Li et al.42 Considering the high-risk surgical procedures,
the extended hospitalization periods, and various postop-
erative complications of tracheal stenosis, prevention of
restenosis and minimalization of surgical intervention
with the topical application of MMC might be successful
treatment modality for laryngotracheal stenosis.
CONCLUSION
We demonstrated that MMC has the potential to
reverse the TGFβ-induced myoﬁbroblast differentiation
because we observed signiﬁcant decrease in α-SMA
expression and wound-healing activity in MMC-treated
cells. Antiﬁbrotic effects of MMC also were veriﬁed on
human primary vocal cord ﬁbroblast cell cultures. Our
results support that MMC can be applied to suppress
upper airway stenosis by overturning the myoﬁbroblast
phenotype.
BIBLIOGRAPHY
1. Nanthakumar CB, Hatley RJ, Lemma S, Gauldie J, Marshall RP,
Macdonald SJ. Dissecting ﬁbrosis: therapeutic insights from the small-
molecule toolbox. Nat Rev Drug Discov 2015;14:693–720.
2. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac ﬁbrosis:
the ﬁbroblast awakens. Circ Res 2016;118:1021–1040.
3. Singh T, Sandulache VC, Otteson TD, et al. Subglottic stenosis examined as
a ﬁbrotic response to airway injury characterized by altered mucosal ﬁbro-
blast activity. Arch Otolaryngol Head Neck Surg 2010;136:163–170.
4. Sztano B, Torkos A, Rovo L. The combined endoscopic management of con-
genital laryngeal web. Int J Pediatr Otorhinolaryngol 2010;74:212–215.
5. Rovo L, Jori J, Brzozka M, Czigner J. Minimally invasive surgery for poste-
rior glottis stenosis. Otolaryngol Head Neck Surg 1999;121:153–156.
6. Rovo L, Venczel K, Torkos A, Majoros V, Sztano B, Jori J. Endoscopic aryte-
noid lateropexy for isolated posterior glottic stenosis. Laryngoscope 2008;
118:1550–1555.
7. Sztano B, Szakacs L, Madani S, Toth F, Bere Zs, Castellanos PF, Rovo L.
Comparison of endoscopic techniques designed for posterior glottic steno-
sis: a cadaver morphometric study. Laryngoscope 2014;124:705–710.
8. Karagiannidis C, Velehorschi V, Obertrifter B, Macha HN, Linder A,
Freitag L. High-level expression of matrix-associated transforming growth
factor-beta1 in benign airway stenosis. Chest 2006;129:1298–1304.
9. Simpson CB, James JC. The efﬁcacy of mitomycin-C in the treatment of lar-
yngotracheal stenosis. Laryngoscope 2006;116:1923–1925.
10. Xi-Qiao W, Ying-Kai L, Chun Q, Shu-Liang L. A review of the effectiveness
of antimitotic drug injections for hypertrophic scars and keloids. Ann
Plast Surg 2009;63:688–692.
11. Guven M, Turan F, Eyibilen A, Akbas A, Erkorkmaz U. A comparison of the
efﬁcacy of 5-ﬂuorouracil/triamcinolone, carnitine and dexamethasone
therapy on wound healing in tracheal injury: potential for preventing tra-
cheal stenosis? Eur Arch Otorhinolaryngol 2012;269:201–206.
12. Bast F, Risteska K, Jovanovic S, Sedlmaier B. The topical application of
mitomycin C in the treatment of scar formation and stenosis in hollow
organs of the head and neck: a ﬁeld report. Laryngorhinootologie 2009;88:
528–533.
13. Camargo PA, Campos AC, Matias JE, Rispoli DZ, Przysiezny PE,
Fonseca VR. Topical mitomycin C effect on swine vocal folds healing. Braz
J Otorhinolaryngol 2006;72:601–604.
14. Chen T, Kunnavatana SS, Koch RJ. Effects of mitomycin-C on normal der-
mal ﬁbroblasts. Laryngoscope 2006;116:514–517.
15. Porter GT, Gadre SA, Calhoun KH. The effects of intradermal and topical
mitomycin C on wound healing. Otolaryngol Head Neck Surg 2006;135:
56–60.
16. Kumar V, Ali MJ, Ramachandran C. Effect of mitomycin-C on contraction
and migration of human nasal mucosa ﬁbroblasts: implications in dacryo-
cystorhinostomy. Br J Ophthalmol 2015;99:1295–1300.
17. Roh JL, Koo BS, Yoon YH, Rha KS, Park CI. Effect of topical mitomycin C
on the healing of surgical and laser wounds: a hint on clinical application.
Otolaryngol Head Neck Surg 2005;133:851–856.
18. Roediger FC, Orloff LA, Courey MS. Adult subglottic stenosis: management
with laser incisions and mitomycin-C. Laryngoscope 2008;118:1542–1546.
19. Morishima Y, Nomura A, Uchida Y, et al. Triggering the induction of myoﬁ-
broblast and ﬁbrogenesis by airway epithelial shedding. Am J Respir Cell
Mol Biol 2001;24:1–11.
20. Jester JV, Huang J, Fisher S, et al. Myoﬁbroblast differentiation of normal
human keratocytes and hTERT, extended-life human corneal ﬁbroblasts.
Invest Ophthalmol Vis Sci 2003;44:1850–1858.
21. Kakudo N, Kushida S, Suzuki K, Ogura T, Notodihardjo PV, Hara T,
Kusumoto K. Effects of transforming growth factor-beta1 on cell motility,
collagen gel contraction, myoﬁbroblastic differentiation, and extracellular
matrix expression of human adipose-derived stem cell. Hum Cell 2012;25:
87–95.
22. Caja L, Dituri F, Mancarella S, et al. TGF-β and the tissue microenviron-
ment: relevance in ﬁbrosis and cancer. Int J Mol Sci 2018;19:1–24.
23. Hansen JK, Thibeault SL. Current understanding and review of the litera-
ture: vocal fold scarring. J Voice 2006;20:110–120.
24. Melkane AE, Matar NE, Haddad AC, et al. Management of postintubation
tracheal stenosis: appropriate indications make outcome differences. Res-
piration 2010;79:395–401.
25. Hoasjoe DK, Franklin SW, Aarstad RF, Day TA, Stucker FJ. Posterior glot-
tic stenosis mechanism and surgical management. Laryngoscope 1997;
107:675–679.
26. Colak N, Nazli Y, Tasoglu I, et al. The effect of Mitomycin-C in reducing
pericardial adhesion after cardiac surgery in rabbits. Can J Cardiol 2013;
29:712–717.
27. Schoenberg ED, Blake DA, Swann FB, et al. Effect of two novel sustained-
release drug delivery systems on bleb ﬁbrosis: an in vivo glaucoma drain-
age device study in a rabbit model. Transl Vis Sci Technol 2015;4:4.
28. Meyenberg A, Goldblum D, Zingg JM, et al. Tocotrienol inhibits prolifera-
tion of human Tenon’s ﬁbroblasts in vitro: a comparative study with
Laryngoscope 00: 2019 Szabó et al.: Laryngeal Stenosis Treatment With Mitomycin-C
7
vitamin E forms and mitomycin C. Graefes Arch Clin Exp Ophthalmol
2005;243:1263–1271.
29. Kaya E, Kibar Y, Yilmaz S, et al. The histopathological effects of intracaver-
nosal Mitomycin-C injection in a rat Peyronie’s disease model. Can Urol
Assoc J 2017;11:441–445.
30. Ayyildiz A, Nuhoglu B, Gulerkaya B, et al. Effect of intraurethral
Mitomycin-C on healing and ﬁbrosis in rats with experimentally induced
urethral stricture. Int J Urol 2004;11:1122–1126.
31. Erard AC, Monnier P, Spiliopoulos A, Nicod L. Mitomycin C for control of
recurrent bronchial stenosis: a case report. Chest 2001;120:2103–2105.
32. Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and
the myoﬁbroblast. Wound Repair Regen 2005;13:7–12.
33. Hirshoren N, Eliashar R. Wound-healing modulation in upper airway steno-
sis: myths and facts. Head Neck 2009;31:111–126.
34. Reinke JM, Sorg H. Wound repair and regeneration. Eur Surg Res 2012;49:
35–43.
35. Kisseleva T, Brenner DA. Mechanisms of ﬁbrogenesis. Exp Biol Med 2008;
233:109–122.
36. Vyas B, Ishikawa K, Duﬂo S, Chen X, Thibeault SL. Inhibitory effects of
hepatocyte growth factor and interleukin-6 on transforming growth
factor-beta1 mediated vocal fold ﬁbroblast-myoﬁbroblast differentiation.
Ann Otol Rhinol Laryngol 2010;119:350–357.
37. Wang PH, Huang BS, Horng HC, Yeh CC, Chen YJ. Wound healing. J Chin
Med Assoc 2018;81:94–101.
38. Walimbe T, Panitch A, Sivasankar MP. An in vitro scaffold-free epithelial-
ﬁbroblast coculture model for the larynx. Laryngoscope 2017;127:185–192.
39. Lanning DA, Diegelmann RF, Yager DR, Wallace ML, Bagwell CE,
Haynes JH. Myoﬁbroblast induction with transforming growth factor-
beta1 and -beta3 in cutaneous fetal excisional wounds. J Pediatr Surg
2000;35:183–187.
40. Bucala R. Review series—inﬂammation & ﬁbrosis. Fibrocytes and ﬁbrosis.
QJM 2012;105:505–508.
41. Yang X, Chen B, Liu T, Chen X. Reversal of myoﬁbroblast differentiation: a
review. Eur J Pharmacol 2014;734:83–90.
42. Li NY, Chen F, Dikkers FG, Thibeault SL. Dose-dependent effect of mitomy-
cin C on human vocal fold ﬁbroblasts. Head Neck 2014;36:401–410.
Laryngoscope 00: 2019 Szabó et al.: Laryngeal Stenosis Treatment With Mitomycin-C
8
